Brief: Aldeyra Therapeutics Results of Phase 2 Clinical Trial Of ADX‑629 In Patients With Chronic Cough
27/06/2023 13:35
June 27 (Reuters) - Aldeyra Therapeutics Inc ALDX.O :
* ALDEYRA THERAPEUTICS ANNOUNCES STATISTICALLY SIGNIFICANT
REDUCTION IN COUGH FREQUENCY IN PHASE 2 CLINICAL TRIAL OF
ADX-629 IN PATIENTS WITH CHRONIC COUGH
* ALDEYRA THERAPEUTICS INC - ADX-629 WAS WELL TOLERATED AND
NO
SAFETY CONCERNS WERE IDENTIFIED
* ALDEYRA THERAPEUTICS INC - PHASE 2 CLINICAL TRIAL OF
ADX-629 IN
MODERATE ALCOHOL-ASSOCIATED HEPATITIS IS EXPECTED TO INITIATE IN
SECOND HALF OF 2023
Source text for Eikon: ID:nBw4YppMsa
Further company coverage: ALDX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug